论文部分内容阅读
目的:评价索拉非尼治疗肝细胞性肝癌的疗效及安全性。方法:总结2008年1月至2009年12月应用索拉非尼治疗的45例肝细胞性肝癌患者的临床资料。结果:33例接受过1次以上实体瘤治疗疗效评价标准(RECIST)评价者中,服药后6周RECIST评价时27例肿瘤稳定,5例肿瘤进展,1例肿瘤出现病灶缩小,10例美国东部肿瘤协作组(ECOG)体力状况评分改善;不良反应一般在服药后1~2周左右出现,在所有接受治疗的患者中,共14例发生较严重(3~4级)的不良反应,不能耐受不良反应而减少药物剂量者11例,3例停药。药物不良反应在减少剂量并予一定对症支持治疗后大多可以缓解。结论:索拉非尼可延长晚期肝细胞性肝癌患者的肿瘤无进展生存时间,且耐受性良好,是治疗晚期原发性肝癌的新选择。
Objective: To evaluate the efficacy and safety of sorafenib in the treatment of hepatocellular carcinoma. METHODS: Clinical data of 45 hepatocellular carcinoma patients treated with sorafenib between January 2008 and December 2009 were summarized. RESULTS: Of the 33 patients who received one or more evaluation criteria for solid tumor treatment efficacy (RECIST), 27 patients were stable at the 6th week after RECIST evaluation, tumors were stable in 5 cases, tumors progressed in 1 case, and tumors were reduced in 1 case. ECOG physical status scores improved; Adverse reactions usually occurred about 1 to 2 weeks after taking the drug. In all patients undergoing treatment, a total of 14 patients experienced severe (grades 3 to 4) adverse reactions. 11 cases were reduced by adverse drug reactions and 3 cases were discontinued. Adverse drug reactions can be relieved after reducing the dose and providing symptomatic supportive treatment. Conclusion: Sorafenib can prolong the progression-free survival of patients with advanced hepatocellular carcinoma and is well tolerated. It is a new choice for the treatment of advanced primary liver cancer.